Kenmare revenues double in first half
FTSE 250 miner Kenmare doubled revenues in the first half and said it expected a significant improvement in production in the latter part of the year.
FTSE 250 miner Kenmare doubled revenues in the first half and said it expected a significant improvement in production in the latter part of the year.
Revenues were up 95% to $109m from $56m the year before, as the company benefitted from price increases and the falling away of legacy contracts.
But the firm said first half revenues had been hit by lower production and the carrying forward of a significant amount of ilmenite at 2011 price levels.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Pre-tax profits came in at £38.8m, up from a loss of $14.2m in the same period of 2011.
Earnings per share were 1.61c, rising from the 0.59c loss reported the previous year.
"While the near-term global economic environment remains uncertain, continued industrialisation, and the ensuing urbanisation taking place in emerging economies, are expected to support strong demand for products that consume titanium feedstocks and zircon, " said Managing Director Michael Carvill.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Keir Starmer's 100 days in office: chaos and misery
Keir Starmer has achieved 100 days in office. The bumbling and grasping prime minister needs a guiding mission
By Emily Hohler Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published